公司資料
Genelux 股價、新聞與催化劑
- 股票代碼:
- GNLX
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
2.70 USD (-1.46%)
收盤價
最後更新: 2026年8月17日
132M USD
市值
股價為何變動
As of Aug 17, 2026, GNLX closed down 1.46% at $2.70. No new same-company headline was identified in the current news window.
公司概覽
Oncolytic Immunotherapy
Genelux develops replication-competent oncolytic viruses designed to destroy tumor cells and stimulate systemic antitumor immunity. Its platform is being studied through regional and systemic administration approaches.
Olvi-Vec
Olvi-Vec is the company's lead vaccinia-virus candidate. The registrational OnPrime/GOG-3076 study evaluates intraperitoneal Olvi-Vec followed by chemotherapy and bevacizumab in platinum-resistant or refractory ovarian cancer.
Systemic Lung-Cancer Programs
Genelux is also advancing systemic Olvi-Vec studies in lung cancer, seeking to extend the platform beyond tumors accessible through localized administration.
未來催化劑
- Topline data from the Phase 3 OnPrime/GOG-3076 study of Olvi-Vec in ovarian cancer in the second half of 2026.
- Dose-escalation updates from systemic Olvi-Vec studies in lung cancer during 2026.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。